UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1245-8
Program Prior Authorization/Notification
Medication Ilumya™ (tildrakizumab-asmn)*
*Ilumya is excluded from coverage for the majority of our benefits
P&T Approval Date 5/2018, 2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 7/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Ilumya (tildrakizumab-asmn) is an interleukin-23 antagonist indicated for the treatment of
adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or
phototherapy.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Ilumya will be approved based on both of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) Patient is not receiving Ilumya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx
(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Ilumya will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Ilumya therapy
-AND-
(2) Patient is not receiving Ilumya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
© 2024 UnitedHealthcare Services, Inc.
1
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx
(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• *Ilumya is excluded from coverage for the majority of our benefits
• Supply limits, Step Therapy, and/or Medical Necessity may be in place.
4. Reference:
1. Ilumya [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; December 2022.
Program Prior Authorization/Notification - Ilumya (tildrakizumab)
Change Control
5/2018 New program
2/2019 Annual review with no change to clinical criteria.
2/2020 Annual review. Added coverage exclusion statement.
2/2021 Annual review. Updated reauthorization duration.
2/2022 Annual review with no changes to coverage criteria. Updated
reference.
2/2023 Annual review. Updated listed examples from Humira to adalimumab
and added Rinvoq. Added state mandate footnote.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review with no changes to coverage criteria. Updated
reference.
© 2024 UnitedHealthcare Services, Inc.
2